KLDiscovery Releases Client Portal in EMEA
KLDiscovery Inc. (“KLDiscovery” or “KLD” or the “Company”), an industry leader in global data management, information governance, eDiscovery, and advisory services solutions, announces the availability of its one-of-a-kind Client Portal in EMEA. KLDiscovery’s Client Portal is a proprietary data visualisation tool that offers users on-demand access to business intelligence and analytics from anywhere, anytime.
By making critical case information and financial metrics easily accessible, Client Portal helps users gain visibility, insight, and control with powerful features such as:
- Dynamic and interactive dashboards with dozens of real-time data points
- In-depth visualizations for specific projects and entire customer portfolios
- Customisable reporting
- Budget tracking
- Grouping of data points by service type, entity, or time period (daily, monthly, quarterly, or annually)
“This technology is unique in the eDiscovery industry.Client Portal transforms our customers' ability to quickly obtain critical business intelligence and financial insights,” said Chris Weiler, Chief Executive Officer. “In our efforts to continuously increase the value proposition of our solutions, Client Portal creates yet another compelling reason for clients in EMEA to leverage KLD’s technology to their benefit.”
“We’re thrilled to now offer this groundbreaking product to our European clients,” said Danny Zambito, Chief Operating Officer. “For over a year, Client Portal has been a complete game changer, helping our clients in other regions of the globe, including North America and APAC, take full control of their portfolios of legal matters. Our clients throughout EMEA are about to gain a whole new level of transparency that’s only available through KLDiscovery.”
For more information about Client Portal, visit the Company’s website. KLDiscovery’s existing clients in EMEA who are interested in taking advantage of Client Portal’s benefits are invited to reach out directly to their Company representative to learn more.
About KLDiscovery
KLDiscovery provides technology-enabled services and software to help law firms, corporations, and government agencies solve complex data challenges. With 25 locations across 16 countries, KLDiscovery is a global leader in delivering best-in-class data management, information governance, and eDiscovery solutions to support the litigation, regulatory compliance, and internal investigation needs of clients. Serving organisations for over 30 years, KLDiscovery offers data collection and forensic investigation, early case assessment, data processing, application software and data hosting for web-based document reviews, and managed document review services. In addition, through its global Ontrack data management business, KLDiscovery delivers world-class data recovery, disaster recovery, email extraction and restoration, data destruction, and tape management. KLDiscovery has been recognised as one of the fastest growing companies in North America by both Inc. Magazine (Inc. 5000) and Deloitte (Deloitte's Technology Fast 500), and CEO Chris Weiler was a 2014 Ernst & Young Entrepreneur of the Year™. Additionally, KLDiscovery is a Relativity Certified Partner and maintains ISO/IEC 27001 Certified data centers around the world. Visit www.kldiscovery.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005137/en/
Contact information
Krystina Jones
888.811.3789
krystina.jones@kldiscovery.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 07:22:00 CEST | Press release
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP
AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 04:00:00 CEST | Press release
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA,PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s comp
The Podium Welcomes the Conquerors of 2023 Taklimakan Rally!2.6.2023 03:33:00 CEST | Press release
Among the 97 autos and 37 motorcycles who have started the Rally in Aksu on May 20, 76 autos and 31 motos have successfully withstood the tough challenges and reached the finish line. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005748/en/ As the 15th edition of Taklimakan Rally, the 2023 Taklimakan Rally lasts for 13 days. The 4258 km total stage contains 1 SSS, 9 stages and 2 rest days. The rally sets foot in the south west of Xinjiang and covers 3 regions of Aksu, Kashgar and Hotan. The multi-terrain stages together with the beautiful scenery has attracted 231 competitors from China and abroad to participate. In the auto category, the final victory goes to Zi Yungang/Wang Zengrong from Shanxi Yunxiang Team. Team BAIC contributes to the podium with Zhang Guoyu/Oriol Mena Valdearcos and Liu Yangui/Chen Feng listed the 2nd and 3rd place. As to the moto, Bradley John Cox and Arunas Gelazninkas continued their good per
UAE’s In-Country Value Projects Driving Billions to Local Firms1.6.2023 18:40:00 CEST | Press release
More than $27.23 billion has been redirected to the local economy since the UAE Ministry of Industry and Advanced Technology (MoIAT) and ADNOC launched major in-country value programs to support domestic industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005886/en/ Sideline of Make It In The Emirates Forum (Photo: AETOSWire) Speaking at the Make in the Emirates Forum today, His Excellency Abdulla Al Shamsi, Assistant Undersecretary of MoIAT, said more than $14.43 billion of investment was redirected to the local economy last year alone, an increase of 25 percent year-on-year. “The National In-Country Value Program is a nationwide program that speaks one language across many different sectors,” HE said. “It’s one methodology and this is something we’re very proud of because it benefits the private sector and when the private sector sees this it helps them prepare, invest, and spend.” The forum heard how the Nati
Carbios and Indorama Ventures Reaffirm Partnership to Build First-of-a-kind PET Biorecycling Plant in France1.6.2023 18:30:00 CEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005872/en/ Carbios and Indorama Ventures reaffirm partnership to build first-of-a-kind PET biorecycling plant in France Carbios (Euronext Growth Paris: ALCRB), a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles, and Indorama Ventures Public Company Limited (IVL) (Bloomberg ticker IVL.TB), a global sustainable chemical producer, announce today the signing of a non-binding Memorandum of Understanding (MOU) to form a Joint Venture for the construction of the world’s first PET biorecycling plant in France1. Based on and subject to the comprehensive terms set out in the MOU, Indorama Ventures plans to mobilize about €110 million for the Joint Venture in equity and non-convertible loan financing2, pending final engineering documentation and final economic feasibility studies. Both parties have